

Contract Number	Amount Obligated	Total Estimated Con	Center	Awardee Name	Awardee Address	BAA Number	Award Title	Charge Description
75F40126C00039	\$872,653.00	\$872,653.00	CDRH	University of Maryland, College Park	3112 Lee Bldg 7809 Regents Dr College Park MD 207425100	FY25C1AP20	Machine Learning-Guided 3D Nanoprinting of a Retinal Vascular Phantom Library	(I) Modernize development and evaluation of FDA-regulated products
75F40126C00019	\$1,004,344.00	\$1,004,344.00	CDRH	Malcova Inc.	39655 EUREKA DR NEWARK CA 945604806	FY25C1CP50	BREVITY: A Patient-Derived Digital-Twin Platform for Breast-Cancer Imaging	(I) Modernize development and evaluation of FDA-regulated products
75F40126C00020	\$1,736,780.00	\$1,736,780.00	CDRH	Nudge BG Inc.	725 OLD FARM RD THOUSAND OAKS CA 91360	FY25C1CP51	Automated Insulin Delivery Interoperability Framework Extension	(I) Modernize development and evaluation of FDA-regulated products
75F40126C00021	\$1,667,902.00	\$1,667,902.00	CDRH	North Carolina Community Health Care Association	4917 WATERS EDGE DR STE 165 RALEIGH NC 27606	FY25C1EP7	Making Older Americans and Rural Populations Healthier - Supporting Rural Clinical Investigator Readiness	(I) Modernize development and evaluation of FDA-regulated products
75F40126C00035	\$1,294,042.00	\$1,294,042.00	CDRH	Cognita Imaging Inc.	845 LIVE OAK AVE MENLO PARK CA 940254911	FY25C2BP11	Virtual Subject Matter Expert Agents for Radiology Report Evaluation	(II) Strengthen post-market surveillance and labeling of FDA-regulated products
75F40126C00025	\$325,000.00	\$325,000.00	CDER	Institute for Clinical Pharmacodynamics	242 BROADWAY STE 101 SCHENECTADY NY 12305	FY25C3BP4	Development of Susceptibility Guidance for Daptomycin and Enterococcus Species Using Pharmacometric Approaches	(III) Invigorate public health preparedness and response of the FDA, patients, and consumers
75F40126C00208	\$918,951.00	\$918,951.00	OCS	Diagnostic Biochips, Inc .	801 Cromwell Park Dr Ste 103 Glen Burnie MD 21061- 2539	FY26C1AP10	A High-Throughput Physiology Tool for NAMs-based Safety Studies	(I) Modernize development and evaluation of FDA-regulated products
75F40126C00096	\$1,517,015.00	\$2,998,734.00	OCE	The Brigham and Womens Hospital INC	75 Francis St Boston, MA 02115	FY26C1AP15	A Long-Term Vascular MPS to Assess Cyclic Cardiovascular Toxicity of Oncology Drugs	(I) Modernize development and evaluation of FDA-regulated products
75F40126C00089	\$645,503.00	\$1,667,347.00	CDER	University of Florida	1523 UNION RD RM 207 GAINESVILLE FL 32611	FY26C1AP28	Mechanistic Gastric NAM and PBPK Framework to Interpret Bioequivalence of Oral Peptide Drug Products	(I) Modernize development and evaluation of FDA-regulated products
75F40126C00080	\$884,879.12	\$1,742,521.12	OCE	American Type Culture Collection	10801 UNIVERSITY BLVD MANASSAS VA 201102204	FY26C1AP30	A NAM-Aligned Pediatric Glioblastoma CIVM with EV-Enabled Non-Destructive Molecular Fidelity Assessment	(I) Modernize development and evaluation of FDA-regulated products
75F40126C00101	\$534,032.00	\$760,505.00	CDER	University of Strathclyde	16 Richmond ST Glasgow G1 1XQ	FY26C1AP5	Enhancing Regulatory Confidence in Pediatric Bioequivalence Through Validated TIM Based Mechanistic Platforms and Model Integrated Evidence	(I) Modernize development and evaluation of FDA-regulated products
75F40126C00156	\$861,756.00	\$861,756.00	CDER	University of Massachusetts Lowell	220 Pawtucket St Ste 400 Lowell MA 018543573	FY26C1BP12	Multiscale Digital Twin Framework for Flexible Biomanufacturing	(I) Modernize development and evaluation of FDA-regulated products
75F40126C00086	\$1,845,938.00	\$1,845,938.00	CDER	Purdue University	SPONSORED PROGRAM SERVICES 302 WOOD ST. (YOUNG HALL) WEST LAFAYETTE IN 479072108	FY26C1BP19	Risk-based digital design and operation of sustainable end-to-end optimal modular pharmaceutical manufacturing systems	(I) Modernize development and evaluation of FDA-regulated products
75F40126C00085	\$1,365,711.00	\$1,365,711.00	CDER	Purdue University	2550 Northwestern Ave STE 1120 West Lafayette IN 47906	FY26C1BP21	Microwave-Assisted Lyophilization for Advanced Manufacturing of Pharmaceuticals and Biologics in Glass Containers and Bulk Lyobeads	(I) Modernize development and evaluation of FDA-regulated products
75F40126C00048	\$1,019,732.00	\$1,019,732.00	CDER	Physical Sciences Inc.	20 NEW ENGLAND BUSINESS CTR DR ANDOVER MA 018101022	FY26C1BP25	Advanced Control Techniques for Product Temperature during Pharmaceutical Lyophilization: A feedforward and feedback approach	(I) Modernize development and evaluation of FDA-regulated products
75F40126C00066	\$2,682,546.00	\$6,954,936.00	OCE	Trustees of the University of Pennsylvania	3451 WALNUT STREET 5TH FLOOR, FRANKLIN BUILD PHILADELPHIA PA 19104- 6205	FY26C1BP32	Targeted polymer-lipid nanoparticle platform for bioPROTAC-mediated degradation of oncofusion proteins in Ewing Sarcoma	(I) Modernize development and evaluation of FDA-regulated products
75F40126C00098	\$733,525.00	\$733,525.00	CDER	RESEARCH CENTER PHARMACEUTICAL ENGINEERING GMBH	INFFELDGASSE 13 GRAZ 8010	FY26C1BP33	Next generation process development and quality control in protein lyophilization using mechanistic and AI approaches	(I) Modernize development and evaluation of FDA-regulated products

75F40126C00054	\$1,517,240.00	\$1,517,240.00	CDER	The National Institute for Pharmaceutical Technology & Education	717 DELAWARE ST SE STE 482 MINNEAPOLIS MN 554142959	FY26C1BP4	Smart Quality Control for 3D Printed Solid Dosage Forms using In-Situ Metrology and Machine Learning	(I) Modernize development and evaluation of FDA-regulated products
75F40126C00093	\$456,721.00	\$456,721.00	CBER	University of Massachusetts Lowell	220 Pawtucket St Ste 400 Lowell MA 018543573	FY26C1BP9	AI-Assisted Digital Twin Platform for Real-Time Lyophilization Process Development and Scale-Up	(I) Modernize development and evaluation of FDA-regulated products
75F40126C00177	\$947,034.00	\$947,034.00	CDRH	Barco Inc.	3059 Premiere PKWY STE 400 Duluth Georgia 30097-4905	FY26C1CP1	Advanced physical and digital slides for Characterization, Performance and Interoperability Assessment of Digital Pathology Systems	(I) Modernize development and evaluation of FDA-regulated products
75F40126C00056	\$2,456,000.00	\$2,456,000.00	CDRH	The Research Foundation for The State University of New York	BINGHAMTON NY 139026000 PO BOX 6000	FY26C1CP12	Estimation of In-vivo Tissue Properties using Clinical MR Thermometry Data	(I) Modernize development and evaluation of FDA-regulated products
75F40126C00087	\$1,173,033.00	\$2,432,643.00	CDER	University of Connecticut	438 Whitney Rd Extention Unit 1133 Storrs, CT 06269	FY26C1CP13	Investigating the impact of diastereomers and synthesis-related impurities on the immunogenicity of oligonucleotides	(I) Modernize development and evaluation of FDA-regulated products
75F40126C00154	\$599,999.00	\$599,999.00	CDER	University of Connecticut	438 Whitney Rd Extention Unit 1133 Storrs, CT 06269	FY26C1CP17	Release mechanisms of oral modified-release products: dissolution method development and mechanistic insights	(I) Modernize development and evaluation of FDA-regulated products
75F40126C00088	\$657,981.00	\$1,207,750.00	CDER	University of Connecticut	438 Whitney Rd Extention Unit 1133 Storrs, CT 06269	FY26C1CP2	Mechanistic Insights into Aggregation Behavior and Predictive Modeling of Long-Acting Injectable Nano-Suspensions	(I) Modernize development and evaluation of FDA-regulated products
75F40126C00082	\$256,446.00	\$867,832.00	CVM	The Texas A&M University Health Science Center	8441 Riverside Pkwy SUITE 3100 BRYAN TX 77807	FY26C1CP22	Impact of Critical Material Attributes of Hard Compressed and Soft Chewable Animal Products on Critical Quality Attributes: Chewing, In Vitro Dissolution, In Vitro Permeation, Bioavailability, and Stability	(I) Modernize development and evaluation of FDA-regulated products
75F40126C00059	\$511,219.00	\$789,844.00	CDER	University of Connecticut	438 Whitney Rd Extention Unit 1133 Storrs, CT 06269	FY26C1CP3	Advancing LNG-IUSs Development Through Accelerated Testing, IVIVR, and Predictive Modeling Approaches	(I) Modernize development and evaluation of FDA-regulated products
75F40126C00060	\$688,145.00	\$990,864.00	CDER	University of Texas at Austin	110 INNER CAMPUS DR AUSTIN TX 78712-1139	FY26C1CP31	Effects of Material Property and Manufacturing Process on the Physicochemical Attributes and in vivo Performance of Peptide Implants	(I) Modernize development and evaluation of FDA-regulated products
75F40126C00063	\$575,554.00	\$1,650,102.00	CDER	Simulations Plus, Inc.	42505 10th ST W Lancaster CA 93534-7059	FY26C1CP40	Development of a Predictive PBPK Framework Informed by In Vitro Assays for Oral Lipid-Based Drug Delivery Systems	(I) Modernize development and evaluation of FDA-regulated products
75F40126C00097	\$499,922.00	\$499,922.00	CDER	Uppsala Universitet	P.O. Box Uppsala 75105	FY26C1CP41	Robust clinical endpoint bioequivalence studies using model-integrated evaluation approaches	(I) Modernize development and evaluation of FDA-regulated products
75F40126C00107	\$500,000.00	\$500,000.00	CDER	University of California San Francisco	1855 FOLSOM STREET SAN FRANCISCO CA 94143 BOX 0816	FY26C1CP48	A Multi-Agent AI System for High-Throughput PBPK Modeling: Predicting Formulation Effect on Drug Absorption and Human Pharmacokinetics	(I) Modernize development and evaluation of FDA-regulated products
75F40126C00071	\$352,968.00	\$1,083,957.00	CDER	Certara UK Limited	SHEFFIELD SOUTH YORKSHIRE S2 4S JOHN STREET	FY26C1CP53	Advancing integration of in vitro topical product characterization and skin permeation data with PBPK approaches to study the influence of excipients and compositional changes on drug products bioequivalence	(I) Modernize development and evaluation of FDA-regulated products
75F40126C00153	\$540,907.00	\$540,907.00	CDER	Purdue University	SPONSORED PROGRAM SERVICES 302 WOOD ST. (YOUNG HALL) WEST LAFAYETTE IN 479072108	FY26C1CP7	Developing Regulatory Science Tools for Oral Peptide Delivery: Integrating Mechanistic Understanding with Predictive In Vitro Models	(I) Modernize development and evaluation of FDA-regulated products
75F40126C00100	\$1,149,236.00	\$1,149,236.00	CDRH	Emory University	201 DOWMAN DR NE ATLANTA GA 30322	FY26C1EP1	Evaluating the Fit-for-Purpose of Patient Reported Outcomes for Medical Device Evaluation	(I) Modernize development and evaluation of FDA-regulated products
75F40126C00158	\$948,781.00	\$948,781.00	CDRH	Digital Medicine Society Inc.	90 CANAL ST FL 4 BOSTON MA 02114	FY26C1EP3	Modernizing Outcome Data for Opioid Use Disorder (MOD-OD): A prospective study to modify episodic patient reports into continuous sensor-based relapse risk assessments for safety surveillance	(I) Modernize development and evaluation of FDA-regulated products
75F40126C00068	\$933,028.00	\$1,583,356.00	OCE	Dana-Farber Cancer Institute, Inc.	450 BROOKLINE AVENUE BOSTON MA 022155450	FY26C1EP4	A Multiomics Approach to Improving the Identification of the Side Effects of Immune Checkpoint Inhibitors (ICIs)	(I) Modernize development and evaluation of FDA-regulated products
75F40126C00181	\$1,256,810.00	\$1,256,810.00	OCE	Duke University	0 DUKE UNIVERSITY DURHAM NC 277088990	FY26C1FP3	Towards ML-Powered, Efficient and Robust Inference of Average and Individual Treatment Effects for Novel Clinical Trials in Rare Diseases	(I) Modernize development and evaluation of FDA-regulated products

75F40126C00055	\$752,304.00	\$752,304.00	OCE	The University of Texas MD Anderson Cancer Center	1515 HOLCOMBE BLVD BOX 1676 HOUSTON TX 77030	FY26C1FP7	Evaluating Bayesian Effective Sample Size and Decision Criteria for Pediatric and Rare Disease Trials	(I) Modernize development and evaluation of FDA-regulated products
75F40126C00081	\$749,762.00	\$749,762.00	CDRH	DUKE UNIVERSITY	0 Duke University Durham NC 27708-8990	FY26C1IP1	AI-Driven Adaptive Adolescent Patient Preference Elicitation for Regulatory Decision Making	(I) Modernize development and evaluation of FDA-regulated products
75F40126C0012	\$1,456,427.00	\$1,456,427.00	CDER	Duke University	0 Duke University Durham NC 27708-8990	FY26C1IP3	Developing Evidence-Based Training Methodologies for Implementing FDA’s Patient-Focused Drug Development Guidance	(I) Modernize development and evaluation of FDA-regulated products
75F40126C00094	\$749,621.00	\$749,621.00	CDRH	University of Maryland, Baltimore	220 Arch ST, Office Level 2 Baltimore, MD 212011531	FY26C1JP1	REAL-AI:PE - Real-world Evidence And Localized AI imaging Testbed for Pulmonary Embolism	(I) Modernize development and evaluation of FDA-regulated products
75F40126C00120	\$1,994,855.00	\$1,994,855.00	CVM	University of Maine System	CONTROLLER'S OFFICE 65 TEXAS AVE BANGOR ME 044014324	FY26C1JP17	Determining the pharmacokinetics of PFAS contamination in dairy cattle across lactations	(I) Modernize development and evaluation of FDA-regulated products
75F40126C00064	\$6,000,000.00	\$12,000,000.00	CDRH	The Medical Device Innovation Consortium	1655 Fort Myer Dr FL12 Arlington, VA 22209-2403	FY26C1JP2	Enhancing Infrastructure for Real-World Data (RWD) Sources and Real-World Evidence(RWE) Generation in Medical Devices	(I) Modernize development and evaluation of FDA-regulated products
75F40126C00065	\$6,515,098.00	\$35,194,704.00	CDRH	Rutgers The State University of New Jersey	33 Knightsbridge Rd, 2nd FL east Piscataway, NJ 08854	FY26C1JP8	Identification and Performance Assessment of Medical Devices in Electronic Health Record Data – Development of a Transparent and Repeatable Framework to Enhance Medical Device Integration in Real-World Evidence Generation	(I) Modernize development and evaluation of FDA-regulated products
75F40126C00157	\$286,130.00	\$286,130.00	CDER	George Mason University	4400 UNIVERSITY DR FAIRFAX VA 22030	FY26C1JP9	Regulatory Grade Frameworks for Assessing Record Linkage Uncertainty in Real-World Evidence	(I) Modernize development and evaluation of FDA-regulated products
75F40126C00217	\$2,131,932.00	\$2,131,932.00	CDRH	Emergency Care Research Institute	5200 BUTLER PIKE PLYMOUTH MEETING PA 194621241	FY26C2AP11	Development and Implementation of a Surveillance and Evaluation System for AI-enabled Medical Devices	(II) Strengthen post-market surveillance and labeling of FDA-regulated products
75F40126C00069	\$634,642.00	\$634,642.00	CDER	The National Institute for Pharmaceutical Technology & Education	717 DELAWARE ST SE STE 482 MINNEAPOLIS MN 554142959	FY26C2AP9	Advanced CMC Index and Intelligence Platform for Drug Quality Control, Shortage Prediction, and Strategic Reshoring	(II) Strengthen post-market surveillance and labeling of FDA-regulated products
75F40126C00084	\$732,673.00	\$1,411,508.00	CDRH	The Regents of the University of California	1855 FOLSOM ST STE 425 SAN FRANCISCO CA 9410334	FY26C2BP1	Scalable monitoring procedures for generative AI-based medical devices	(II) Strengthen post-market surveillance and labeling of FDA-regulated products
75F40126C00070	\$435,178.88	\$435,178.88	CDER	Universitat St.Gallen 1592134	DUFOURSTRASSE 50 ST. GALLEN SG 9000	FY26C2DP2	Beyond Compliance: Integrating Quality Culture and Risk in Pharmaceutical Quality Management Oversight	(II) Strengthen post-market surveillance and labeling of FDA-regulated products
75F40126C00083	\$1,500,000.00	\$9,900,000.00	OC	University of Nevada, Reno (with Wyss Institute at Harvard, Stanford University, and Beth Israel Deaconess Medical Center)	1664 N. VIRGINIA ST 204 ROSS HALL, MS 325 RENO NV 89557	FY26C3AP4	A Cross-Species Immune Organ Chip Reference Framework for Regulatory Evaluation of Vaccine and Antiviral Medical Countermeasures	(III) Medical Countermeasures (MCMs)
75F40126C00151	\$580,601.00	\$580,601.00	CDER	Johns Hopkins University	W-400 WYMAN PARK 3400 N CHARLES ST BALTIMORE MD 212182685	FY26C3BP5	Leveraging Real World Data to Develop External Controls for Invasive Fungal Infection Trials	(III) Invigorate public health preparedness and response of the FDA, patients, and consumers
75F40126C00197	\$293,829.00	\$293,829.00	CDER	Carelane LLC	69 W 107th St Apt 2D New York NY 100253284	FY26C3BP6	Advancing the Development of External Controls for Invasive Fungal Infection Trials - University Hospital Cologne; Carelane LLC	(III) Invigorate public health preparedness and response of the FDA, patients, and consumers
75F40126C00095	\$995,374.00	\$995,374.00	CDER	The Task Force for Global Health Inc.	330 W PONCE DE LEON AVENUE DECATUR GA 30030	FY26C3CP11	Developing Standardized Case Definitions for Cannabis Adverse Events	(III) Invigorate public health preparedness and response of the FDA, patients, and consumers
75F40126C00123	\$1,863,392.00	\$1,957,886.00	CDRH	MedTech Innovator	907 WESTWOOD BLVD SUITE 1067 LOS ANGELES CA 90024	FY26C3EP3	A Publicly Available FDA-Hosted Playbook for Strategic Planning of End-to-End Stakeholder Evidence Generation in Medical Device Development	(III) Invigorate public health preparedness and response of the FDA, patients, and consumers
\$63,603,152.00		\$120,774,129.00						